<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35608443</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>305</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Radiology</Title><ISOAbbreviation>Radiology</ISOAbbreviation></Journal><ArticleTitle>Lung Abnormalities Detected with Hyperpolarized <sup>129</sup>Xe MRI in Patients with Long COVID.</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>717</EndPage><MedlinePgn>709-717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.220069</ELocationID><Abstract><AbstractText>Background Post-COVID-19 condition encompasses symptoms following COVID-19 infection that linger at least 4 weeks after the end of active infection. Symptoms are wide ranging, but breathlessness is common. Purpose To determine if the previously described lung abnormalities seen on hyperpolarized (HP) pulmonary xenon 129 (<sup>129</sup>Xe) MRI scans in participants with post-COVID-19 condition who were hospitalized are also present in participants with post-COVID-19 condition who were not hospitalized. Materials and Methods In this prospective study, nonhospitalized participants with post-COVID-19 condition (NHLC) and posthospitalized participants with post-COVID-19 condition (PHC) were enrolled from June 2020 to August 2021. Participants underwent chest CT, HP <sup>129</sup>Xe MRI, pulmonary function testing, and the 1-minute sit-to-stand test and completed breathlessness questionnaires. Control subjects underwent HP <sup>129</sup>Xe MRI only. CT scans were analyzed for post-COVID-19 interstitial lung disease severity using a previously published scoring system and full-scale airway network (FAN) modeling. Analysis used group and pairwise comparisons between participants and control subjects and correlations between participant clinical and imaging data. Results A total of 11 NHLC participants (four men, seven women; mean age, 44 years &#xb1; 11 [SD]; 95% CI: 37, 50) and 12 PHC participants (10 men, two women; mean age, 58 years &#xb1;10; 95% CI: 52, 64) were included, with a significant difference in age between groups (<i>P</i> = .05). Mean time from infection was 287 days &#xb1; 79 (95% CI: 240, 334) and 143 days &#xb1; 72 (95% CI: 105, 190) in NHLC and PHC participants, respectively. NHLC and PHC participants had normal or near normal CT scans (mean, 0.3/25 &#xb1; 0.6 [95% CI: 0, 0.63] and 7/25 &#xb1; 5 [95% CI: 4, 10], respectively). Gas transfer (Dlco) was different between NHLC and PHC participants (mean Dlco, 76% &#xb1; 8 [95% CI: 73, 83] vs 86% &#xb1; 8 [95% CI: 80, 91], respectively; <i>P</i> = .04), but there was no evidence of other differences in lung function. Mean red blood cell-to-tissue plasma ratio was different between volunteers (mean, 0.45 &#xb1; 0.07; 95% CI: 0.43, 0.47]) and PHC participants (mean, 0.31 &#xb1; 0.10; 95% CI: 0.24, 0.37; <i>P</i> = .02) and between volunteers and NHLC participants (mean, 0.37 &#xb1; 0.10; 95% CI: 0.31, 0.44; <i>P</i> = .03) but not between NHLC and PHC participants (<i>P</i> = .26). FAN results did not correlate with Dlco) or HP <sup>129</sup>Xe MRI results. Conclusion Nonhospitalized participants with post-COVID-19 condition (NHLC) and posthospitalized participants with post-COVID-19 condition (PHC) showed hyperpolarized pulmonary xenon 129 MRI and red blood cell-to-tissue plasma abnormalities, with NHLC participants demonstrating lower gas transfer than PHC participants despite having normal CT findings. &#xa9; RSNA, 2022 <i>Online supplemental material is available for this article.</i> See also the editorial by Parraga and Matheson in this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grist</LastName><ForeName>James T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0001-7223-4031</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collier</LastName><ForeName>Guilhem J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-1874-4775</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Huw</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3838-1529</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minsuok</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1074-8082</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3779-5615</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Eid</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laws</LastName><ForeName>Aviana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0021-2922</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Violet</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cross</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eves</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8714-3896</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durrant</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2975-4821</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9868-6183</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Roger</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0717-4551</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Rolf F</ForeName><Initials>RF</Initials><Identifier Source="ORCID">0000-0002-1334-1264</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Betty</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1239-9608</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbins</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-4975-0609</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Jim M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-7246-8660</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7449-5793</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gleeson</LastName><ForeName>Fergus</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5121-3917</Identifier><AffiliationInfo><Affiliation>From the Department of Radiology (J.T.G., H.W., M.C., G.A.E., A.L., V.M., K.J., S.C., A.E., M.D., A.M., F.G.) and Oxford Interstitial Lung Disease Service (E.F.), Oxford University Hospitals NHS Trust, Oxford, UK; Department of Physiology, Anatomy, and Genetics (J.T.G., P.A.R.), Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research (J.T.G., B.R.), and Department of Oncology (F.G.), University of Oxford, Old Road Headington, Oxford 0X3&#x2009;7DQ, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (J.T.G.); POLARIS, Department of Infection Immunity and Cardiovascular Disease (G.J.C., J.M.W.), and Department of Infection, Immunity, and Cardiovascular Disease (R.T.), University of Sheffield, Sheffield, UK; Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK (M.K.); and GE Healthcare, Munich, Germany (R.F.S.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FS/18/13/33281</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SP/14/6/31350</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008894/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Radiology</MedlineTA><NlmUniqueID>0401260</NlmUniqueID><ISSNLinking>0033-8419</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014979">Xenon Isotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Radiology. 2022 Dec;305(3):718-720. doi: 10.1148/radiol.221098</RefSource><PMID Version="1">35608450</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Radiology. 2023 Oct;309(1):e239025. doi: 10.1148/radiol.239025</RefSource><PMID Version="1">37906016</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014979" MajorTopicYN="Y">Xenon Isotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosures of conflicts of interest: </b><b>J.T.G.</b> No relevant relationships. <b>G.J.C.</b> No relevant
relationships. <b>H.W.</b> No relevant relationships. <b>M.K.</b> No
relevant relationships. <b>M.C.</b> No relevant relationships.
<b>G.A.E.</b> No relevant relationships. <b>A.L.</b> No relevant
relationships. <b>V.M.</b> No relevant relationships. <b>K.J.</b> No
relevant relationships. <b>S.C.</b> No relevant relationships.
<b>A.E.</b> No relevant relationships. <b>M.D.</b> No relevant
relationships. <b>A.M.</b> No relevant relationships. <b>R.T.</b>
British Heart Foundation intermediate clinical fellowship; institutional funding
from Janssen-Cilag; support to attend meetings from Janssen-Cilag.
<b>RFS</b> GE Healthcare employee; stock options in GE Healthcare.
<b>B.R.</b> Grants from British Heart Foundation and Oxford Centre of
Research Excellence. <b>P.A.R.</b> No relevant relationships.
<b>J.M.W.</b> No relevant relationships. <b>E.F.</b> Conference
presentations for palliative care general medicine national training course; on
the Celltrion advisory board for Regdanviman <b>F.G.</b> Equipment from
Polarean and GE Healthcare; grant from Innovate UK; consulting fees from
Sensyne; on the advisory boards of AstraZeneca and Polarean; president of the
European Society of Thoracic Imaging; stock in Optellum, RAIQC, and
OxSonics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35608443</ArticleId><ArticleId IdType="pmc">PMC9134268</ArticleId><ArticleId IdType="doi">10.1148/radiol.220069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C , Huang L , Wang Y , et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study . Lancet 2021. ; 397 ( 10270 ): 220 &#x2013; 232 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health
Organization
. 
A clinical case definition of
post COVID-19 condition by a Delphi consensus, 6 October
2021
. 
https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
Accessed September 12, 2021
.
</Citation></Reference><Reference><Citation>Han X , Fan Y , Alwalid O , et al. . Six-month Follow-up Chest CT findings after Severe COVID-19 Pneumonia . Radiology 2021. ; 299 ( 1 ): E177 &#x2013; E186 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F , Yang L , Liang B , et al. . Chest CT Patterns from Diagnosis to 1 Year of Follow-up in Patients with COVID-19 . Radiology 2022. ; 302 ( 3 ): 709 &#x2013; 719 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515211</ArticleId><ArticleId IdType="pubmed">34609153</ArticleId></ArticleIdList></Reference><Reference><Citation>Grist JT , Chen M , Collier GJ , et al. . Hyperpolarized 129Xe MRI Abnormalities in Dyspneic Participants 3 Months after COVID-19 Pneumonia: Preliminary Results . Radiology 2021. ; 301 ( 1 ): E353 &#x2013; E360 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168952</ArticleId><ArticleId IdType="pubmed">34032513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing K , Ruppert K , Jiang Y , et al. . Regional mapping of gas uptake by blood and tissue in the human lung using hyperpolarized xenon-129 MRI . J Magn Reson Imaging 2014. ; 39 ( 2 ): 346 &#x2013; 359 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758375</ArticleId><ArticleId IdType="pubmed">23681559</ArticleId></ArticleIdList></Reference><Reference><Citation>Motiejunaite J , Balagny P , Arnoult F , et al. . Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors . Eur Respir J 2021. ; 58 ( 2 ): 2101578 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361302</ArticleId><ArticleId IdType="pubmed">34385265</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier GJ , Eaden JA , Hughes PJC , et al. . Dissolved 129Xe lung MRI with four-echo 3D radial spectroscopic imaging: Quantification of regional gas transfer in idiopathic pulmonary fibrosis . Magn Reson Med 2021. ; 85 ( 5 ): 2622 &#x2013; 2633 .</Citation><ArticleIdList><ArticleId IdType="pubmed">33252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M , Doganay O , Matin TN , Povey T , Gleeson FV . CT-based Airway Flow Model to Assess Ventilation in Chronic Obstructive Pulmonary Disease: A Pilot Study . Radiology 2019. ; 293 ( 3 ): 666 &#x2013; 673 .</Citation><ArticleIdList><ArticleId IdType="pubmed">31617794</ArticleId></ArticleIdList></Reference><Reference><Citation>Strassmann A , Steurer-Stey C , Lana KD , et al. . Population-based reference values for the 1-min sit-to-stand test . Int J Public Health 2013. ; 58 ( 6 ): 949 &#x2013; 953 .</Citation><ArticleIdList><ArticleId IdType="pubmed">23974352</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo TK , Li MY . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research . J Chiropr Med 2016. ; 15 ( 2 ): 155 &#x2013; 16 3 [Published correction appears in J Chiropr Med 2017;16(4):346.].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913118</ArticleId><ArticleId IdType="pubmed">27330520</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and
Care Excellence
. 
RCGP and SIGN publish
guideline on managing the long-term effects of
COVID-19
. 
https://www.nice.org.uk/news/article/nice-rcgp-and-sign-publish-guideline-on-managing-the-long-term-effects-of-covid-19.
Published December 18, 2020. Accessed September 12,
2021
.
</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Piiper J , Scheid P . Blood-gas equilibration in lungs . In: West JB , ed . Pulmonary Gas Exchange . London, England: : Academic Press; , 1980. ; 131 &#x2013; 171 .</Citation></Reference><Reference><Citation>Stewart NJ , Leung G , Norquay G , et al. . Experimental validation of the hyperpolarized 129Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung disease . Magn Reson Med 2015. ; 74 ( 1 ): 196 &#x2013; 207 .</Citation><ArticleIdList><ArticleId IdType="pubmed">25106025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E , Vlok M , Venter C , et al. . Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin . Cardiovasc Diabetol 2021. ; 20 ( 1 ): 172 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Roughton FJ , Forster RE . Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries . J Appl Physiol 1957. ; 11 ( 2 ): 290 &#x2013; 302 .</Citation><ArticleIdList><ArticleId IdType="pubmed">13475180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammarappallil JG , Rankine L , Wild JM , Driehuys B . New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging . J Thorac Imaging 2019. ; 34 ( 2 ): 136 &#x2013; 150 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392051</ArticleId><ArticleId IdType="pubmed">30801449</ArticleId></ArticleIdList></Reference><Reference><Citation>Inui S , Yoon SH , Doganay O , Gleeson FV , Kim M . Impaired pulmonary ventilation beyond pneumonia in COVID-19: A preliminary observation . PLoS One 2022. ; 17 ( 1 ): e0263158 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789183</ArticleId><ArticleId IdType="pubmed">35077496</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng J . Sample size estimation: how many individuals should be studied? Radiology 2003. ; 227 ( 2 ): 309 &#x2013; 313 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12732691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>